247 related articles for article (PubMed ID: 9083475)
1. Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
Chen L; Zoulíková I; Slaninová J; Barany G
J Med Chem; 1997 Mar; 40(6):864-76. PubMed ID: 9083475
[TBL] [Abstract][Full Text] [Related]
2. Syntheses and biological activities of parallel and antiparallel homo and hetero bis-cystine dimers of oxytocin and deamino-oxytocin.
Chen L; Bauerová H; Slaninová J; Barany G
Pept Res; 1996; 9(3):114-21. PubMed ID: 8875590
[TBL] [Abstract][Full Text] [Related]
3. Solid-phase synthesis and biological activity of the parallel dimer of deamino-oxytocin.
Munson MC; Lebl M; Slaninová J; Barany G
Pept Res; 1993; 6(3):155-9. PubMed ID: 8318747
[TBL] [Abstract][Full Text] [Related]
4. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8.
Flouret G; Chaloin O; Slaninová J
J Pept Sci; 2003 Jun; 9(6):393-401. PubMed ID: 12846485
[TBL] [Abstract][Full Text] [Related]
5. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
6. Chemical syntheses and biological studies on dimeric chimeras of oxytocin and the V(2)-antagonist, d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.
Chen L; Golser R; Machová A; Slaninová J; Barany G
J Med Chem; 1999 Dec; 42(24):5002-9. PubMed ID: 10585209
[TBL] [Abstract][Full Text] [Related]
7. On-resin native chemical ligation for cyclic peptide synthesis.
Tulla-Puche J; Barany G
J Org Chem; 2004 Jun; 69(12):4101-7. PubMed ID: 15176835
[TBL] [Abstract][Full Text] [Related]
8. Cyclization of disulfide-containing peptides in solid-phase synthesis.
Albericio F; Hammer RP; García-Echeverría C; Molins MA; Chang JL; Munson MC; Pons M; Giralt E; Barany G
Int J Pept Protein Res; 1991 May; 37(5):402-13. PubMed ID: 1917296
[TBL] [Abstract][Full Text] [Related]
9. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.
Flouret G; Majewski T; Balaspiri L; Brieher W; Mahan K; Chaloin O; Wilson L; Slaninová J
J Pept Sci; 2002 Jul; 8(7):314-26. PubMed ID: 12148781
[TBL] [Abstract][Full Text] [Related]
10. Analogues of neurohypophyseal hormones, oxytocin and arginine vasopressin, conformationally restricted in the N-terminal part of the molecule.
Kowalczyk W; Prahl A; Derdowska I; Sobolewski D; Olejnik J; Zabrocki J; Borovicková L; Slaninová J; Lammek B
J Med Chem; 2006 Mar; 49(6):2016-21. PubMed ID: 16539389
[TBL] [Abstract][Full Text] [Related]
11. [4-(0-methyl)-L-threonine] -oxytocin. Synthesis and uterotonic activity.
Bańkowski K
Pol J Pharmacol Pharm; 1988; 40(3):331-5. PubMed ID: 2853867
[TBL] [Abstract][Full Text] [Related]
12. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity.
Wittelsberger A; Patiny L; Slaninova J; Barberis C; Mutter M
J Med Chem; 2005 Oct; 48(21):6553-62. PubMed ID: 16220972
[TBL] [Abstract][Full Text] [Related]
13. Solid phase synthesis of partially protected tocinoic acid: optimization with respect to resin and protecting groups.
Hlavácek J; Ragnarsson U
J Pept Sci; 2001 Jul; 7(7):349-57. PubMed ID: 11495496
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of oxytocin analogues with replacement of sulfur by carbon gives potent antagonists with increased stability.
Stymiest JL; Mitchell BF; Wong S; Vederas JC
J Org Chem; 2005 Sep; 70(20):7799-809. PubMed ID: 16277299
[TBL] [Abstract][Full Text] [Related]
15. Trimethoxyphenylthio as a highly labile replacement for tert-butylthio cysteine protection in Fmoc solid phase synthesis.
Postma TM; Giraud M; Albericio F
Org Lett; 2012 Nov; 14(21):5468-71. PubMed ID: 23075145
[TBL] [Abstract][Full Text] [Related]
16. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
Fragiadaki M; Magafa V; Borovicková L; Slaninová J; Cordopatis P
Eur J Med Chem; 2007 Jun; 42(6):799-806. PubMed ID: 17316912
[TBL] [Abstract][Full Text] [Related]
18. Modulating oxytocin activity and plasma stability by disulfide bond engineering.
Muttenthaler M; Andersson A; de Araujo AD; Dekan Z; Lewis RJ; Alewood PF
J Med Chem; 2010 Dec; 53(24):8585-96. PubMed ID: 21117646
[TBL] [Abstract][Full Text] [Related]
19. Dose-response behavior on the isolated rat uterus of oxytocin analogs with modifications at binding sites.
Smith CW; Chan S; Walter R
J Pharmacol Exp Ther; 1977 Oct; 203(1):120-4. PubMed ID: 909047
[TBL] [Abstract][Full Text] [Related]
20. Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine.
Gross CM; Lelièvre D; Woodward CK; Barany G
J Pept Res; 2005 Mar; 65(3):395-410. PubMed ID: 15787970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
